On 31 March 2022, NICE provided the first substantive update to its ‘Type 2 diabetes in adults: management’ guideline since 2015. With an estimated 4.4 million people living with type 2 diabetes in the UK, it is vital that pharmacists across sectors are aware of these changes to ensure that they provide patients with the most appropriate care.
In this episode of the PJ Pod, Caitlin Killen, assistant clinical editor, talks through changes to the guidance, including any new recommendations or clarifications with the help of two experts.
Many thanks to Michelle Lam, pharmacy team leader for education and training at St George’s University Hospitals NHS Foundation Trust, and Sallianne Kavanagh, an advanced clinical pharmacist at Sheffield Teaching Hospital and clinical lecturer at the University of Huddersfield, for their expertise.
This episode was produced by Geoff Marsh.
- ‘Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes‘ (November 2015, The New England Journal of Medicine)
- ‘Canagliflozin and cardiovascular and renal events in type 2 diabetes‘ (August 2017, The New England Journal of Medicine)
- ‘Dapagliflozin in patients with heart failure and reduced ejection fraction‘ (November 2019, The New England Journal of Medicine)
- ‘Dapagliflozin in patients with chronic kidney disease‘ (October 2020, The New England Journal of Medicine)
- ‘Canagliflozin and renal outcomes in type 2 diabetes and nephropathy‘ (June 2019, The New England Journal of Medicine)
- ‘Glucagon-like peptide-1 analogues in adults with type 2 diabetes mellitus for glycaemic control‘ (June 2022, The Pharmaceutical Journal)
- ‘Glucose-lowering drugs and cardiovascular risk: how recent outcome trials have informed practice‘ (April 2018, The Pharmaceutical Journal)
- ‘Spotting the signs of acute kidney injury‘ (April 2020, The Pharmaceutical Journal)